Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829328 | 0.98 | NOTUM (0.34) | NOTUMRYR2DPP9DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL27847913 | 0.96 | NOTUM (0.33) | NOTUMRYR2DPP9DPP7DPP8 | |
| SCHEMBL3018741 | 0.78 | NOTUM (0.37) | NOTUMRYR2DPP9DPP7GABRA1 | |
| SCHEMBL29728593 | 0.76 | NOTUM (0.61) | NOTUMDPP9DPP7DPP8HTR1A | |
| SCHEMBL3704956 | 0.76 | NOTUM (0.61) | NOTUMDPP9DPP7DPP8HTR1A | |
| SCHEMBL30595328 | 0.73 | DPP9 (0.41) | NOTUMRYR2DPP9DPP7DPP8 | |
| SCHEMBL9705347 | 0.71 | NOTUM (0.50) | NOTUMDPP9DPP7DPP8ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL27900676 | 0.70 | DPP8 (0.36) | DPP9DPP7DPP8HTR1ATMPRSS2 | |
| SCHEMBL29573372 | 0.70 | NAMPT (0.40) | DPP7CCNA2CDK2CCNA1 | |
| SCHEMBL3643075 | 0.70 | NOTUM (0.42) | NOTUMALDH1A1HTTGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802541-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-04-14 | — | — | EP | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| CN-101909628-B | As leukotriene A4Aryl substituted bridged or fused diamines as hydrolase modulators | JANSSEN PHARMACEUTICA NV | 2013-05-29 | — | — | CN | disclosed |
| CN-101909628-A | As leukotriene A4Aryl substituted bridged or fused diamines as hydrolase modulators | JANSSEN PHARMACEUTICA NV | 2010-12-08 | — | — | CN | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | NOTUM 4205/4885RYR2 3569/4885DPP9 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.